There were 1,084 press releases posted in the last 24 hours and 392,319 in the last 365 days.

Solid Tumors Market is Expected to Gain USD 901.27 Billion by 2029, Size, Share, Recent Trends, Developments, and Future Growth Outlook

Data Bridge Market Research analyses that the solid tumors market was valued at USD 209.61 billion in 2021 and is expected to reach USD 901.27 billion by 2029, registering a CAGR of 20.0% during the forecast period of 2022 to 2029

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Solid Tumors Market" with 100+ market data tables, pie charts, graphs, and figures spread across Pages and an easy-to-grasp full analysis. The market insights gained through an international Solid Tumors market survey report facilitate a more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position a definite brand excellently. With the meticulous competitor analysis covered in this report, businesses can gauge or analyze the strengths and weak points of the competitors which helps build superior business strategies for their own products. For in depth understanding of the market and competitive landscape, the credible Solid Tumors market document serves a lot of parameters and detailed data about the Solid Tumors industry.

The high-quality Solid Tumors market research report is generated by performing high-level market research analysis of key marketplace segments to identify opportunities, challenges, drivers, and market structures for our clients. This industry research report assists in determining and optimizing each stage in the lifecycle of an industrial process that includes engagement, acquisition, retention, and monetization. Being a wide-ranging market research report, it is sure to help grow business in several ways. The leading Solid Tumors market report potentially presents with numerous insights and business solutions that will help stay ahead of the competition.

Data Bridge Market Research analyses that the solid tumors market was valued at USD 209.61 billion in 2021 and is expected to reach USD 901.27 billion by 2029, registering a CAGR of 20.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Grab a PDF Sample of the Solid Tumors Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-solid-tumors-market

Solid tumors are heterotypic collections of a variety of cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. For malignant solid tumors, surgery is currently the most appropriate therapeutic choice. Chemotherapy is usually used with other solid tumor treatments such as surgery and radiation. Solid tumor therapies are pharmaceuticals used to treat tumors including lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, and others. Solid tumor therapeutics are continuing to lead the way in oncology treatments as effective anti-cancer therapy in the global oncology therapeutics market.

Solid tumors are created by the accumulation of aberrant tissues that do not contain any liquid or cyst in the case of cancer. There are two types of solid tumors: benign and malignant. The treatment of solid tumors is difficult, and it necessitates coordinated actions by a variety of healthcare professionals, including surgeons, radiologists, radiation specialists, oncologists, and others. As a result, chemotherapy, radiation, and/or surgery are used to treat the majority of solid tumors.

The Solid Tumors Market is Dominated by Firms Such as

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Gilead Sciences, Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.)
  • Lupin (India)
  • Allergan (Ireland)

Fundamental Aim of Solid Tumors Market Report

In the Solid Tumors Industry, every company has goals, but this report focuses on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.

  • Major alterations to the Solid Tumors Market in the near future.
  • Notable Market rivals around the world.
  • The Solid Tumors Market's Future Scope and Product Outlook
  • Future-promising emerging markets.
  • The Market Presents Difficult Challenges and Threats.
  • Sales data and profiles of the world's leading Solid Tumors manufacturers

Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-solid-tumors-market

Recent Development

  • In May 2021, Amgen announced the U.S. Food and Drug Administration (FDA) approval for LUMAKRAS (sotorasib) for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS was given priority approval due to its high overall response rate (ORR) and short response time. Continued approval for this indication could be conditional on a confirmatory trial demonstrating and documenting clinical trials.

Opportunities for Key Players:

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the solid tumors market growth

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for solid tumor market growth during the forecast period.

Key Market Segments Covered in Solid Tumors Industry Research

By Site of Origin

  • Prostrate Cancer
  • Ovarian Cancer
  • Bladder Cancer

By Therapy Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tyrosine kinase inhibitors
  • Hedgehog pathway inhibitor

By Route of Administration

  • Oral
  • Parenteral

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Key Growth Drivers:

  • Increasing prevalence of different forms of metastatic cancers

The rising prevalence of different forms of metastatic cancer is estimated to enhance the market's growth. In 2012, the World Health Organization (WHO) estimated that 8.2 million people died worldwide as a result of various types of malignancies. Lung, colorectal, breast, and liver cancers were among the most common cancers, with lung, colorectal, and breast cancers being the most common. Brain tumors (medulloblastoma and glioma) and neuroblastoma are the most frequent solid tumors; rhabdomyosarcoma and osteosarcoma are less common solid cancers.

  • Increasing investment in healthcare infrastructure

Another significant factor influencing the growth rate of solid tumors market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness and growing demand for highly effective chemotherapeutic agents will expand the solid tumors market. Additionally, the sedentary lifestyle of people and increasing incidences of several cases of solid tumors will result in the expansion of solid tumors market. The rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Browse a Detailed Summary of the Research Report @ https://www.databridgemarketresearch.com/reports/global-solid-tumors-market

Solid Tumors Market Regional Analysis/Insights:

The countries covered in the solid tumors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the solid tumors market because of the rising prevalence of solid tumors and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing number of geriatric population and surging level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

Restraints/Challenges:

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the solid tumors market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This solid tumors industry report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the solid tumors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Solid Tumors Market: Regulations
  6. Market Overview
  7. Global Solid Tumors Market, By Site of Origin
  8. Global Solid Tumors Market, By Therapy Type
  9. Global Solid Tumors Market, By Route of Administration
  10. Global Solid Tumors Market, By End User
  11. Global Solid Tumors Market, By Distribution Channel
  12. Global Solid Tumors Market, By Region
  13. Global Solid Tumors Market: Company Landscape
  14. SWOT Analyses
  15. Company Profile
  16. Questionnaires
  17. Related Reports

Get the Full Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-solid-tumors-market

Explore More Reports:

  • Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI)), Grade (Grade 1 (Low-Grade Tumor, Grade 2 (Intermediate-Grade Tumor, Grade 3 (High-Grade Tumor)), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-neuroendocrine-tumors-market
  • Asia-Pacific Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific) https://www.databridgemarketresearch.com/reports/asia-pacific-neuroendocrine-tumors-market
  • Europe Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI)), Grade (Grade 1 (Low-Grade Tumor, Grade 2 (Intermediate-Grade Tumor, Grade 3 (High-Grade Tumor)), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania, Rest of Europe) https://www.databridgemarketresearch.com/reports/europe-neuroendocrine-tumors-market
  • Middle East and Africa Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centres, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait & Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-neuroendocrine-tumors-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com


Primary Logo